Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors.
Brain tumor
Central nervous system
Neuro-oncology
Neurosurgery
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
16
10
2019
accepted:
17
12
2019
revised:
16
10
2019
pubmed:
1
1
2020
medline:
22
6
2021
entrez:
1
1
2020
Statut:
ppublish
Résumé
To evaluate overall survival for atypical teratoid rhabdoid tumors (ATRTs) in relation to extent of surgical resection. The neurosurgical tumor databases from three UK Pediatric centers (University Hospital of Wales, Alder Hey and Royal Manchester Children's Hospital) were analyzed. Patients with a diagnosis of ATRT were identified between 2000 and 2018. Data was collected regarding demographics, extent of resection, complications, and overall survival. Twenty-four patients diagnosed with ATRT underwent thirty-eight operations. The age range was 20 days to 147 months (median 17.5 months). The most common location for the tumor was the posterior fossa (nine patients; 38%). Six patients (25%) underwent a complete total resection (CTR), seven (29%) underwent a near total resection (NTR), eight (33.3%) underwent a subtotal resection (STR), and three patients (12.5%) had biopsy only. Two-thirds of patients who underwent a CTR are still alive, as of March 2019, compared to 29% in the NTR and 12.5% in the STR groups. Out of the thirty-eight operations, there were a total of twenty-two complications, of which the most common was pseudomeningocele (27%). The extent of surgical resection (p = 0.021), age at surgery (p = 0.00015), and the presence of metastases at diagnosis (0.015) significantly affected overall survival. Although these patients are a highly vulnerable group, maximal resection is recommended where possible, for the best chance of long-term survival. However, near total resections are likely beneficial when compared with subtotal resections and biopsy alone. Maximal surgical resection should be combined with adjuvant therapies for the best long-term outcomes.
Identifiants
pubmed: 31889208
doi: 10.1007/s00381-019-04478-5
pii: 10.1007/s00381-019-04478-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
713-719Références
Cancer Manag Res. 2016 Sep 16;8:115-125
pubmed: 27695363
Anticancer Res. 2006 Sep-Oct;26(5B):3773-9
pubmed: 17094400
Genes Chromosomes Cancer. 2010 Feb;49(2):176-81
pubmed: 19902524
J Korean Neurosurg Soc. 2018 May;61(3):302-311
pubmed: 29742888
Childs Nerv Syst. 2018 Apr;34(4):627-638
pubmed: 29218405
Neurosurg Focus. 2006 Jan 15;20(1):E11
pubmed: 16459991
Pediatr Blood Cancer. 2011 Dec 1;57(6):978-85
pubmed: 21796761
Cancer Cell. 2016 Dec 12;30(6):891-908
pubmed: 27960086
J Clin Oncol. 2005 Mar 1;23(7):1491-9
pubmed: 15735125
Cancer Res. 1999 Jan 1;59(1):74-9
pubmed: 9892189
Cancer. 2012 Aug 1;118(15):3812-21
pubmed: 22180295
Cancer. 1978 May;41(5):1937-48
pubmed: 206343
J Clin Oncol. 2009 Jan 20;27(3):385-9
pubmed: 19064966
Cancer. 2012 Sep 1;118(17):4212-9
pubmed: 22213196
J Clin Neurosci. 2001 Jan;8(1):1-3
pubmed: 11148073
J Neurooncol. 2017 Mar;132(1):155-162
pubmed: 28102486
J Neurooncol. 2009 Apr;92(2):177-83
pubmed: 19048188
J Neurooncol. 2005 Mar;72(1):85-8
pubmed: 15803380
Acta Neurochir (Wien). 2015 Apr;157(4):589-96
pubmed: 25646852
J Neurosurg. 1996 Jul;85(1):56-65
pubmed: 8683283
J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42
pubmed: 12142780
J Pediatr Hematol Oncol. 2009 Sep;31(9):651-63
pubmed: 19707161
Clin Cancer Res. 2002 Nov;8(11):3461-7
pubmed: 12429635
Eur J Cancer. 2012 Feb;48(3):353-9
pubmed: 22023887
J Clin Oncol. 2004 Jul 15;22(14):2877-84
pubmed: 15254056
Expert Rev Anticancer Ther. 2005 Oct;5(5):907-15
pubmed: 16221059
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Cell. 2016 Mar 14;29(3):379-393
pubmed: 26923874